Abstract: Purpose/Background: Deficits in N-methyl-D-aspartate receptor (NMDAR) function contribute to symptoms and cognitive dysfunction in schizophrenia and are associated with impaired generation of eventrelated potential measures including auditory mismatch negativity. Parallel studies of the NMDAR agonist D-serine have suggested that sensitivity of these measures to glutamate-based interventions is related to symptomatic and cognitive response. Bitopertin is a selective inhibitor of glycine transport. This study investigates effects of bitopertin on NMDAR-related event-related potential deficits in schizophrenia. Implications/Conclusions: These findings represent the first assessment of the effect of bitopertin on neurophysiological biomarkers. Bitopertin did not significantly affect either symptoms or NMDAR-related biomarkers at the dose tested (10 mg). Mismatch negativity showed high test-retest reliability, supporting its use as a target engagement measure.
A ll current treatments for schizophrenia, including both typical and atypical antipsychotics, function primarily by blocking dopamine (D 2 ) receptors. An alternative formulation for schizophrenia focuses on disturbances of brain glutamatergic neurotransmission, particularly at N-methyl-D-aspartate-type glutamate receptors (NMDARs).
1,2 N-Methyl-D-aspartate-type glutamate receptor models of schizophrenia are based upon the ability of agents such as phencyclidine or ketamine to induce symptoms and cognitive deficits closely resembling those of schizophrenia by blocking neurotransmission at NMDAR. [2] [3] [4] In addition, glutamatergic models specifically account for impairments in the generation of neurophysiological measures, such as auditory mismatch negativity (MMN) and visual P1, which index local circuit dysfunction within sensory brain regions in schizophrenia. Deficits in auditory MMN generation [5] [6] [7] [8] and visual P1 9 have been replicated extensively in schizophrenia. Mismatch negativity has previously been shown to index NMDAR function dysfunction 6, [9] [10] [11] [12] and appears to be unaffected by treatment with either typical or atypical antipsychotics, 9, 13, 14 suggesting relative specificity for glutamatergic versus dopaminergic mechanisms.
The present study evaluates utility of these biomarkers for evaluating target engagement and predicting outcome for bitopertin, a recently developed high-affinity glycine type I (GlyT1) transport inhibitor. 15 Prior clinical studies with bitopertin have been mixed. 16 In an initial phase II study for persistent negative symptoms, bitopertin showed significant beneficial effect at doses of 10 and 30 mg/d in a per-protocol, but not intent-to-treat, analysis. 15 A follow-up phase III program targeting patients with predominant negative symptoms failed to show beneficial effects. 17 However, a highly significant (P = 0.0023) effect was observed in 1 of 3 phase III studies targeting suboptimally controlled positive symptoms, although other findings were negative, 18 and further development has been abandoned.
The present project builds from a program for D-serine funded by National Institute of Mental Health, a direct agonist at the glycine modulatory site of the NMDAR. 19 Although results of individual clinical studies of D-serine have also been mixed, 20 recent studies suggest significant beneficial effects on persistent negative symptoms in both adult [21] [22] [23] and clinically high risk 24 populations. We recently observed significant improvement in symptoms (d = 0.8) and MMN generation (d = 2.3) after a 6-week treatment with D-serine, 25 along with significant beneficial effects in on plasticity (learning) and MMN 26 after acute, intermittent (once weekly) D-serine treatment. The present report investigates effects of bitopertin at the dose that was most effective in the clinical development programs (10 mg), using similar neurophysiological methods as our prior positive D-serine studies. 25, 26 We hypothesized that (1) MMN and visual P1 would be reliable, supporting the use of neurophysiological biomarkers for translational drug development in schizophrenia, and (2) bitopertin would improve symptoms of schizophrenia to the extent that they induced objective benefit in MMN and Visual P1.
MATERIALS AND METHODS

Subjects
Written informed consent for participation was obtained from all subjects. Subjects were aged 18 to 64 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of schizophrenia or schizoaffective disorder. Subjects were psychiatrically stable as evidenced by a Clinical Global Impression of Change score 27 of 3 or 4 in the 2-week postscreening visit, and were excluded for unstable medical illness, current clozapine treatment, psychotropic medication changes within 4 weeks, alcohol/substance abuse within past month, or dependence within past 6 months. Functional impairment was determined by a Global Assessment of Functioning score between 31 and 50, inclusive, and a Clinical Global Impression-Severity Scale score of greater than or equal to 4. Subjects were excluded for hemoglobin level of less than 130 g/L in males or less than 120 g/L in females (because of potential bitopertin effects on erythropoiesis), and for Abnormal Involuntary Movement Scale global severity score of greater than 3 (moderate) and/or Facial and Oral Movement items with a score of greater than 2 (mild).
Study Design
This was a 6-week, single-center, randomized, double-blind, placebo-controlled, 2-arm parallel study in which subjects were randomized in a 3:2 ratio to fixed dose bitopertin (10 mg) versus placebo conducted at the Nathan Kline Institute, Orangeburg, NY. All subjects were receiving a stable dose of antipsychotic medications for 4 weeks or more.
Outcomes
Mismatch negativity and visual P1 were obtained using previously described methods, 9,25 assessed at baseline, and, at the end of treatment, collected in a single session per day. Symptom assessments were performed biweekly using the Positive and Negative Symptom Scale (PANSS) total and 5-factor scores. 28 The MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) consensus cognitive battery (MCCB) (minus the social cognition domain) 29 was used for neurocognitive assessment, administered before and after each treatment phase.
Statistical Analysis
Subjects were compared between randomized groups with respect to baseline characteristics using χ 2 test for categorical variables and 2-samples t test for continuous variables. Linear mixed-effects models, 30 which included indicators for treatment (bitopertin or placebo), were used and adjusted for the baseline levels of the outcomes. Because PANSS was measured repeatedly over the course of treatment, we included time by treatment interactions. In addition to random subject intercepts, these mixedeffects models included random subject slopes to account for the correlation between the repeated biweekly assessments of subjects' symptoms. Between-group effect sizes were calculated using Cohen d expressed in SD units. Values in the text are mean ± SD unless otherwise specified.
RESULTS
Sample Description (Fig. S1 , http://links.lww.com/JCP/A449) Twenty-nine subjects were enrolled (bitopertin, 17; placebo, 12). Two patients in the bitopertin group were prematurely withdrawn from treatment because of nonserious adverse events, yielding 27 completers. There were no demographic differences between bitopertin and placebo groups, and all subjects were receiving antipsychotic medications (Table 1 ). In comparison with prior positive bitopertin studies, 15, 18 which limited chlorpromazine Placebo subjects were receiving the following antipsychotics alone or in combination: aripiprazole and risperidone, 33% each; olanzapine and haloperidol, 25% each; quetiapine, 17%; fluphenazine, lurasidone, and perphenazine, 8% each.
Within group % does not add up to 100% owing to antipsychotic polypharmacy. *Mean ± SD or %.
equivalents (CPZEs) 31 to less than 600 mg, CPZEs for the present study were higher.
Outcomes
Voltage-topography distribution was similar to, but reduced compared with controls (Fig. S2, (Table 2) . Change in PANSS factor scores and the MCCB was also nonsignificant ( Table 2) . No clinically significant side effects were observed. Two patients assigned to bitopertin were withdrawn: 1 for hernia pain not related to study treatment and 1 for abnormal liver function tests possibly related to study treatment.
Relationship Between CPZEs and Outcomes
Given the relationship between antipsychotic dose and PANSS outcome in prior studies, 18 the relationship between CPZEs and PANSS was assessed. Within the bitopertin group, a positive correlation was seen between final positive symptoms and CPZEs (r = 0.51, P = 0.044). No significant correlation between CPZEs and PANSS was seen in the placebo group (r = 0.2, P = 0.46).
DISCUSSION
The present paper reports on the effects of bitopertin on NMDAR-based biomarkers in schizophrenia. Bitopertin did not significantly affect either symptoms or NMDAR-related biomarkers at the dose tested (10 mg). By contrast, we have previously observed significant interrelated effects of the glycine-site agonist D-serine on both symptoms and MMN. 25, 26 The lack of change of MMN in the present study is consistent with lack of clinical effect, and thus suggests that MMN may have negative, as well as positive, predictive value in predicting efficacy of novel compounds. Mismatch negativity may be useful as a functional target engagement biomarker for translational drug development targeting the glutamate system. 32 The small magnitude change observed with bitopertin is consistent with small magnitude improvements that have been observed with high-affinity GlyT1 inhibitors such as AMG-747 33 or Org25935. 34 Given our small sample, a potential small effect size change on both symptoms and biomarkers cannot be excluded. Nevertheless, clinical results are markedly smaller than those we recently observed with D-serine using a similar design 25 or those that have been reported with the naturally occurring compound sarcosine (N-methylglycine), which serves as an antagonist of both GlyT1 and "System A" type small neutral amino acid transporter 2 (SNAT2). System A transporters are also targeted by therapeutic concentrations of clozapine 35 and, thus, may be a critical component of the sarcosine response. Nevertheless, future studies investigating sarcosine effects on neurophysiological biomarkers are required.
Several limitations of the present study need to be acknowledged. First, only a single dose of bitopertin was used. Thus, significant effects might have been obtained at lower or higher doses. However, the dose used is the dose that has proven most effective across the development program. Second, patients in general were on high doses of antipsychotic, with approximately 40% of subjects receiving treatment with multiple antipsychotics. In the 22, 25 and, thus, cannot fully account for the differential findings in the present versus the previous study. Third, the overall n was small, although significant results were seen with similar n's in our recent D-serine studies. 22, 25 Finally, we did not investigate the potential utility of bitopertin in facilitating cortical plasticity, 26 which may be another beneficial effect of NMDAR agonist-based treatment.
In summary, we have previously observed that D-serine, an NMDAR glycine-site agonist that improves negative symptoms across clinical studies, also increases MMN amplitudes during both chronic and intermittent use. 25, 26 The present study demonstrates that the high-affinity GlyT1 inhibitor bitopertin, which has failed in recent clinical trials targeting negative symptoms, also failed to improve MMN in the present study. Future studies are needed to determine the basis for the differential clinical effects noted with direct agonists (eg, glycine, D-serine) or with the GlyT1/SNAT2 inhibitor sarcosine versus more recently developed high-affinity GlyT1 antagonists. Dr Javitt reports having received consulting payments within the last 2 years from Pfizer, Autifony, Glytech, Sunovion, Forum, and Takeda. He has received research support from Roche. He holds intellectual property rights for use of NMDA modulators in treatment of neuropsychiatric disorders. He holds equity in Glytech, AASI, and NeuroRx and serves on the advisory board of Promentis and NeuroRx. All other coauthors report no conflicts.
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